Sequenom, Inc., a leading provider of genetic analysis solutions, announced that Portland, Ore.-based Oregon Health & Science University (OHSU) Cancer Institute has purchased a MassARRAY system for use in the discovery, development and testing of biomarker panels for rapid classification and characterization of cancer. The OHSU Cancer Institute is recognized worldwide for its cancer research.
"This placement at the prestigious OHSU Cancer Institute is a tremendous validation of MassARRAY technology's ability to advance the development of multiple biomarker sets or panels, allowing for the precise classification of tumours. This information could eventually guide rational cancer therapy and improve patient care," said Michael Monko, Sequenom senior vice president, sales & marketing. "Evidence of the MassARRAY's superior sensitivity and accuracy in characterizing heterogeneous tumours has been demonstrated in several studies recently published in peer-reviewed scientific journals."
"In cancer classification, we want to understand the underlying molecular mechanisms so that we can inform patients about their potential outcome and devise strategies for therapeutic intervention," said Dr. Brian Druker, director of the OHSU Cancer Institute. "Specifically, we want to know as much about tumours as quickly and economically as possible and the MassARRAY system will significantly advance our ability to accomplish this."
Sequenom is committed to providing the best genetic analysis products for research and the molecular diagnostic markets. The company makes available superior solutions for genomic science in biomedical research, livestock and agricultural applications and molecular medicine, as well as for various diagnostic markets, including noninvasive prenatal testing, oncology and infectious diseases.
The OHSU Cancer Institute is a National Cancer Institute-designated cancer centre and the only such facility between Sacramento and Seattle. It comprises over 120 clinical researchers, basic scientists and population scientists who work together to translate scientific discoveries into longer and better lives for cancer patients. It is most widely known for its translational research with its contribution to the development of molecularly targeted therapies, including imatinib (Gleevec).